Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Material and methods br Results br Discussion The
2020-03-02

Material and methods Results Discussion The present study shows that peripheral administration of the nonpeptidic corticotropin-releasing factor CRF1 receptor antagonist CP-154,526 before a social defeat inhibits the development of CPP induced with a subthreshold dose of cocaine and reverse
-
br Results br Discussion Drug resistance
2020-03-02

Results Discussion Drug resistance poses the greatest hurdle of achieving high efficacy with AADs in cancer patients. AAD-treated cancer patients often encounter intrinsic and evasive drug resistance that diminishes the therapeutic efficacy to only minor survival benefits in most cancer types.
-
Simon discusses this in the remarks and historical notes sec
2020-03-02

Simon discusses this in the remarks and historical notes section following the general discussion of dynamically defined Verblunsky coefficients; see [12, pp. 706–707]. He points out that “understanding almost periodic Verblunsky coefficients is an intriguing open area” and in particular describes w
-
Therapeutic options targeting intrahepatic resistance are
2020-02-28

Therapeutic options targeting intrahepatic resistance are very limited. Theoretically, the NO-cGMP pathway may be influenced at several sites. Yet, most strategies did not reach clinical practice or yielded disappointing results, such as activators of soluble guanylate cyclase [14], NO releasing der
-
metalloproteinase In conclusion using human liver microsomes
2020-02-28

In conclusion, using human liver microsomes, supersomes from baculovirus-transformed insect cells expressing different human CYP450 isoforms, and V79MZh3A4 cells, MB2 and MB4 were formed from TRB and MC from TRC. The amounts of MB2, MB4, and MC formed were related to the 6β-testosterone hydroxylase
-
Pseudo-UTP br General mechanism of NHEJ NHEJ is
2020-02-28

General mechanism of NHEJ NHEJ is an amazingly versatile pathway that can select specific enzymes which bind to, process, and finally mediate the direct re-ligation of a wide range of DSBs including those that are complex, have incompatible ends, and contain Pseudo-UTP damages [7], [8], [9], [10
-
There exists a glucose residue in
2020-02-28

There exists a glucose residue in the structure of 5. Acid hydrolysis (Supplementary data) followed by TLC comparison with the reference compound as well as GC–MS analysis (l-cysteine methyl ester hydrochloride derivative: tR=22.22min for glucose residue of 5 and 22.46min for the reference compound)
-
hexamethonium The pharmacokinetics properties of compound we
2020-02-28

The pharmacokinetics properties of compound were evaluated in male Sprague Dawley rats following IV (0.7mg/kg) and oral (2.0mg/kg) dosing. The total body clearance and the terminal half-life were 0.73 L/h/kg and 5.1h, respectively. After oral administration the compound showed good bioavailability
-
br Concluding remarks Some of the
2020-02-28

Concluding remarks Some of the clinical trials of putative neutral competitive ERAs have been less successful than anticipated 6, 8, 11. This might be because of underestimation of the complexity of the molecular pharmacology of ETA. To resolve this, it will be necessary to define the signaling m
-
The proliferation of CCA cell
2020-02-28

The proliferation of CCA cell lines can be stimulated by estrogen and other growth factors (Alvaro et al., 2006; DeMorrow, 2009; Mancino et al., 2009). It has also been reported that estrogen positively modulates cholangiocyte proliferation, which is associated with cholangiopathies found in humans
-
In this study CK C prepared from BL DE p
2020-02-28

In this study, CK1δ(ΔC) prepared from BL21(DE3)pλPP had the highest kinase activity among the three isoforms tested when using casein as a substrate. Therefore, CK1δ(ΔC) from BL21(DE3)pλPP has the potential to be a “phosphorylating reagent” that may be widely used in experiments of phosphorylation a
-
To further verify the effect of
2020-02-27

To further verify the effect of BBR on ACAT2 protein expression, we have conducted an in vitro permeability assay using Caco-2 monolayer. This assay has long been used to predict the in vivo CCT251545 analogue and bioavailability of a compound. It was observed that the amount of cholesterol esters
-
Among RAS mutant tumors analyzed
2020-02-27

Among RAS mutant tumors analyzed, we found that the efficacy of either the SHP2 inhibitor SHP099, or combined MEK and SHP2 inhibition was best in those expressing RAS mutations at G12 (Figure 7B). Recent studies revealed that cellular RAS(G12C) activity depends on RTK-mediated nucleotide exchange, a
-
br Application of D receptor PET in psychiatric disorders
2020-02-27

Application of D1-receptor PET in psychiatric disorders Discussion Compared to other markers of the DA system, only a limited number of studies have investigated D1-R in psychiatric disorders. In schizophrenia, which is the most studied condition with a total of 83 identified unique patients,
-
These reactions are used to account
2020-02-27

These reactions are used to account for variations in protein solubility or vesicle recovery. For example, with DGKθ we have found it necessary to maintain the purified enzyme in a solution of 0.01% DDM (DGK-D dilution buffer) in the control reaction to prevent enzyme loss due to aggregation or adhe
16334 records 892/1089 page Previous Next First page 上5页 891892893894895 下5页 Last page